Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables - Net: 2020-2022

  • Fulcrum Therapeutics' Receivables - Net was N/A to $13,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $13,000, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2021, which is 25.00% up from last year.
  • Fulcrum Therapeutics' Receivables - Net amounted to $13,000 in Q3 2022, which was down 96.36% from $357,000 recorded in Q2 2022.
  • In the past 5 years, Fulcrum Therapeutics' Receivables - Net registered a high of $2.5 million during Q4 2021, and its lowest value of $13,000 during Q3 2022.
  • Over the past 3 years, Fulcrum Therapeutics' median Receivables - Net value was $1.2 million (recorded in 2020), while the average stood at $1.2 million.
  • Data for Fulcrum Therapeutics' Receivables - Net shows a peak YoY rose of 25.00% (in 2021) over the last 5 years.
  • Over the past 3 years, Fulcrum Therapeutics' Receivables - Net (Quarterly) stood at $2.0 million in 2020, then rose by 25.00% to $2.5 million in 2021, then reached $13,000 in 2022.
  • Its Receivables - Net was $13,000 in Q3 2022, compared to $357,000 in Q2 2022 and $2.5 million in Q4 2021.